1. Beyond Skeletal-Related Events
Ziya Kirkali 
European Urology Supplements 
Volume 5, Issue 7, Pages (April 2006)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Bisphosphonate inhibition of farnesyl diphosphonate (FPP) synthase. CLO=Clodronate; PAM=Pamidronate; IBA=Ibandronate; RIS=Risedronate; MIN=Minodronate; ZOM=Zoledronic acid. From Dunford et al. [1], with permission.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
Zoledronic acid inhibition of bone metastases in nude mice from human prostate cancer cells. From Corey et al. [2], with permission.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Zoledronic acid inhibition of testosterone-induced revascularization in the prostate of rats. Data from Fournier et al. [5].
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
Zoledronic acid trials in patients with prostate cancer. EAU=European Association of Urology; BM=Bone metastases; TROG=Trans-Tasman Radiation Oncology Group; MRC=Medical Research Council; CECOG=Central European Cooperative Oncology Group.
European Urology Supplements 2006 5, DOI: ( /j.eursup )
Copyright © Terms and Conditions